 | Up a level |
Ruhstaller, T; Thuss-Patience, P; Hayoz, S; Schacher, S; Knorrenschild, J R; Schnider, A; Plasswilm, Ludwig; Budach, W; Eisterer, W; Hawle, H; Mariette, C; Hess, V; Mingrone, W; Montemurro, M; Girschikofsky, M; Schmidt, S C; Bitzer, M; Bedenne, L; Brauchli, P and Stahl, M (2018). Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Annals of oncology, 29(6), pp. 1386-1393. Oxford University Press 10.1093/annonc/mdy105
Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, Jürg; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, Manuela; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; von Moos, R; Zaman, K; ... (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Annals of oncology, 28(2), pp. 305-312. Oxford University Press 10.1093/annonc/mdw622
Koeberle, D; Betticher, D C; von Moos, R; Dietrich, D; Brauchli, P; Baertschi, D; Matter, K; Winterhalder, R; Borner, M; Anchisi, S; Moosmann, P; Kollár, Attila; Saletti, P; Roth, A; Frueh, M; Kueng, M; Popescu, R A; Schacher, S; Hess, V and Herrmann, R (2015). Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of oncology, 26(4), pp. 709-714. Oxford University Press 10.1093/annonc/mdv011
Jörger Messerli, Marianne; Baty, F; Früh, M; Stahel, R A; Betticher, D C; von Moos, Rodica; Ochsenbein, Adrian; Pless, M; Gautschi, O; Rothschild, S; Brauchli, P; Klingbiel, Dirk; Zappa, F; Brutsche, M (2014). Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung cancer, 85(2), pp. 306-313. Elsevier 10.1016/j.lungcan.2014.04.014
Zaman, K; Thürlimann, B; Huober, J; Schönenberger, A; Pagani, O; Lüthi, J; Simcock, M; Giobbie-Hurder, A; Berthod, G; Genton, C; Brauchli, P; Aebi, S (2012). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of oncology, 23(6), pp. 1474-1481. Oxford University Press 10.1093/annonc/mdr448
